ABT vs AEP Stock Comparison

Scores Breakdown

Metric	ABT	AEP
📈 Growth	18/30	12/30
💰 Profitability	17/20	14/20
🏦 Financial Health	18/20	14/20
💵 Valuation	12/20	15/20
⚠️ Risk (lower is better)	4/10	5/10
Overall Score	71/100	60/100

Side-by-Side Summaries

ABT Analysis	AEP Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Across the 8 quarters, Revenues rose from about $4.70B (2024 Q3) to $5.45B (2026 Q2), a ~16% gain, but with volatility (peak around $6.01B in 2025 Q3 and dips in several quarters). Net income ranged from about $0.92B (2024 Q3) to a high of about $1.29B (2025 Q2), ending near $0.75B in 2026 Q2. The trajectory shows modest top-line growth with mixed earnings momentum; the end result is below the initial earnings level despite higher revenue. 💰 Margins & Cash Flow Operating margins have generally trended in the mid-20s percent across several quarters (roughly mid-20s in 2024 Q4 and 2025 Q3; about 23% in 2026 Q2). Cash flow from operations remained positive in most periods (roughly $1.2B–$1.9B), while investing activities were sizable and often negative, pressuring overall free cash flow. Net cash flow patterns reflect ongoing capital spending typical of a regulated utility. 🛡️ Balance Sheet & Liquidity Total assets run around $110B–$122B with equity in the $27B–$33B range and long-term debt near $42B–$50B. Liabilities exceed current assets in several quarters, yielding weaker near-term liquidity (current ratio often below 1). Still, a large asset base and regulated cash flows provide resilience, with debt levels offset by steady rate recovery. ⚠️ Key Drivers & Risks Drivers: Regulated utility demand and rate recovery leverage, ongoing energy transition investments. Risks: Interest-rate/regulatory sensitivity and capital-intensity; earnings can remain volatile around quarterly shifts in demand and tax items.

ABT Analysis

AEP Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Across the 8 quarters, Revenues rose from about $4.70B (2024 Q3) to $5.45B (2026 Q2), a ~16% gain, but with volatility (peak around $6.01B in 2025 Q3 and dips in several quarters). Net income ranged from about $0.92B (2024 Q3) to a high of about $1.29B (2025 Q2), ending near $0.75B in 2026 Q2. The trajectory shows modest top-line growth with mixed earnings momentum; the end result is below the initial earnings level despite higher revenue.

💰 Margins & Cash Flow

Operating margins have generally trended in the mid-20s percent across several quarters (roughly mid-20s in 2024 Q4 and 2025 Q3; about 23% in 2026 Q2). Cash flow from operations remained positive in most periods (roughly $1.2B–$1.9B), while investing activities were sizable and often negative, pressuring overall free cash flow. Net cash flow patterns reflect ongoing capital spending typical of a regulated utility.

🛡️ Balance Sheet & Liquidity

Total assets run around $110B–$122B with equity in the $27B–$33B range and long-term debt near $42B–$50B. Liabilities exceed current assets in several quarters, yielding weaker near-term liquidity (current ratio often below 1). Still, a large asset base and regulated cash flows provide resilience, with debt levels offset by steady rate recovery.

⚠️ Key Drivers & Risks

Drivers: Regulated utility demand and rate recovery leverage, ongoing energy transition investments.
Risks: Interest-rate/regulatory sensitivity and capital-intensity; earnings can remain volatile around quarterly shifts in demand and tax items.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"